Cystamine|cas:51-85-4|西域试剂

Cystamine,99.79%

产品编号：Bellancom-124476| CAS NO：51-85-4| 分子式：C₄H₁₂N₂S₂| 分子量：152.28

Cystamine 是一种 PROTAC linker，属于 alkyl chain 类。可用于合成 PROTAC 分子。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-124476		￥2200.00	杭州北京（现货）
Bellancom-124476		￥3400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cystamine

产品介绍

Cystamine 是游离硫醇半胱胺的二硫化物形式。Cystamine 是一种转谷氨酰胺酶 (Tgase) 抑制剂，具有口服活性。Cystamine 对 caspase-3 也有抑制活性，IC₅₀ 值为 23.6 μM。Cystamine 可用于亨廷顿舞蹈病（HD）等多种疾病的研究。

生物活性

Cystamine is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .

体外研究

Cystamine has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM.
Cystamine (0-500 μM; 0-16 h) inhibits recombinant active caspase-3 in a concentration-dependent manner.
Cystamine (250 μM; 10 h) robustly increases the levels of glutathione.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	uman neuroblastoma SH-SY5Y cells
Concentration:	250, 500 μM
Incubation Time:	0-16 h
Result:	Inhibited the MG132-mediated activation of caspase-3. Inhibited the H2O2-mediated activation of caspase-3. Inhibited caspase-3 activity in a tTG-independent manner.

体内研究
(In Vivo)

Cystamine (oral, i.p.; 112, 225 mg/kg) reduces Tgase activity and GGEL levels, lessens the behavioral and neuropathological severity, and extends survival in R6/2 transgenic HD mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	R6/2 transgenic HD mice
Dosage:	112, 225 mg/kg
Administration:	Intraperitoneal or oral, daily
Result:	Significantly extended survival, improved body weight and motor performance, delayed the neuropathological sequela and significantly altered the levels of Tgase activity and N(Sigma)-(gamma-L-glutamyl)-L-lysine (GGEL) levels.

体内研究

Cystamine (oral, i.p.; 112, 225 mg/kg) reduces Tgase activity and GGEL levels, lessens the behavioral and neuropathological severity, and extends survival in R6/2 transgenic HD mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	R6/2 transgenic HD mice
Dosage:	112, 225 mg/kg
Administration:	Intraperitoneal or oral, daily
Result:	Significantly extended survival, improved body weight and motor performance, delayed the neuropathological sequela and significantly altered the levels of Tgase activity and N(Sigma)-(gamma-L-glutamyl)-L-lysine (GGEL) levels.

体内研究

Cystamine (oral, i.p.; 112, 225 mg/kg) reduces Tgase activity and GGEL levels, lessens the behavioral and neuropathological severity, and extends survival in R6/2 transgenic HD mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	R6/2 transgenic HD mice
Dosage:	112, 225 mg/kg
Administration:	Intraperitoneal or oral, daily
Result:	Significantly extended survival, improved body weight and motor performance, delayed the neuropathological sequela and significantly altered the levels of Tgase activity and N(Sigma)-(gamma-L-glutamyl)-L-lysine (GGEL) levels.

性状

Liquid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (656.69 mM; Need ultrasonic)

H₂O : 100 mg/mL (656.69 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	6.5669 mL	32.8343 mL	65.6685 mL
5 mM	1.3134 mL	6.5669 mL	13.1337 mL
10 mM	0.6567 mL	3.2834 mL	6.5669 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (16.42 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (16.42 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (16.42 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Pure form	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Mathieu Lesort, et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem. 2003 Feb 7;278(6):3825-30. [Content Brief]

. Alpaslan Dedeoglu, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci. 2002 Oct 15;22(20):8942-50. [Content Brief]

. Thomas M Jeitner, et al. Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo. Biosci Rep. 2018 Sep 5;38(5):BSR20180691. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

Cystamine,99.79%

Cystamine

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询